Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
Sue Sha, Damayanthi Devineni, A. Ghosh, et al.·2011·Diabetes Obesity and Metabolism